Cholesterol absorption inhibitor
Ezetimibe
Ezetimibe has a half-life of approximately 22 hours on the Zetia label, the same as the app's 22 hours.1
Ezetimibe after one dose: 50% at ~22 h, 25% at 44 h, 12.5% at 66 h.
Drawn from the half-life in the app's model, ~22 h. The model's figures
- Compound
- Ezetimibe
- Symbol
- EZE
- Family
- Supplements
- Parts
- 14
- References
- 8
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Ezetimibe is sold in the United States as Zetia by Organon LLC, and its label calls it a dietary cholesterol absorption inhibitor.1 The label lists use, in combination with a statin or alone when additional LDL-C lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).1 It also lists use with a statin in pediatric patients 10 years of age and older with HeFH, and with fenofibrate in adults with mixed hyperlipidemia.1 Further listed uses are with a statin and other LDL-C lowering therapies in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH), and as an adjunct to diet for elevated sitosterol and campesterol in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.1 The label gives 2002 as the initial U.S. approval year.1 The app grades the evidence for ezetimibe as strong; IMPROVE-IT was funded by Merck, SHARP by Merck/Schering-Plough Pharmaceuticals together with the Australian National Health and Medical Research Council, the British Heart Foundation and the UK Medical Research Council, and RACING by Hanmi Pharmaceutical.2,3,4
How it works
Sources in this part
The label states that ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.1 Its molecular target has been shown to be the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1), which the label describes as involved in the intestinal uptake of cholesterol and phytosterols.1 The label adds that ezetimibe localizes at the brush border of the small intestine, which decreases the delivery of intestinal cholesterol to the liver.1 It states that this causes a reduction of hepatic cholesterol stores and an increase in LDL receptors.1 In a 2-week clinical trial in 18 hypercholesterolemic patients, the label reports that ezetimibe inhibited intestinal cholesterol absorption by 54% compared with placebo.1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~22 h
- Bioavailability
- 50%
- Typical dose
- 10 mg/day
- Route
- Oral
- Time to peak
- ~6 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the Zetia label reports.
| Parameter | App's figure | Zetia label |
|---|---|---|
| Half-life | ~22 h | Approximately 22 hours for both ezetimibe and ezetimibe-glucuronide1 |
| Bioavailability | 50% | The absolute bioavailability of ezetimibe cannot be determined, as the compound is virtually insoluble in aqueous media suitable for injection1 |
| Time to peak | ~6 h | 4 to 12 hours for ezetimibe and 1 to 2 hours for ezetimibe-glucuronide, after a single 10-mg dose to fasted adults1 |
| Route | Oral | Tablets for oral use1 |
| Typical dose | 10 mg/day | 10 mg orally once daily, with or without food1 |
The label gives the same half-life of approximately 22 hours for both compounds, so the app's 22 hours matches the label for ezetimibe and for ezetimibe-glucuronide.1 The app lists a bioavailability of 50%, while the label states that the absolute bioavailability of ezetimibe cannot be determined, so the app's figure has no matching label figure.1 The app lists a time to peak of about 6 hours, which lies inside the label's 4 to 12 hour range for ezetimibe but not its 1 to 2 hour range for ezetimibe-glucuronide.1 After oral administration, ezetimibe is absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide, ezetimibe-glucuronide.1 Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively.1 The label states that plasma concentration-time profiles exhibit multiple peaks, suggesting enterohepatic recycling.1 Food had no effect on the extent of absorption of the 10-mg tablet, although high-fat meals increased the ezetimibe Cmax by 38%.1 After a single 10-mg dose, mean AUC for total ezetimibe was increased approximately 1.7-fold in mild hepatic impairment and approximately 3- to 4-fold in moderate or severe hepatic impairment, compared with healthy subjects.1
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 22 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Zetia label, two monotherapy trials, US label 20251 | Two multicenter, double-blind, placebo-controlled trials1 | 1719 patients with primary hyperlipidemia, age range 18 to 86 years1 | 12 weeks; ezetimibe against placebo1 | Pooled mean LDL-C change from untreated baseline of -18% with ezetimibe (n=1288) and +1% with placebo (n=431); the label says the reduction "was consistent across age, sex, and baseline LDL-C"1 |
| Cannon and colleagues, IMPROVE-IT, New England Journal of Medicine 20152 | Double-blind randomised trial; funded by Merck, with three authors at Merck2 | 18,144 patients hospitalized for an acute coronary syndrome within the preceding 10 days2 | Simvastatin 40 mg plus ezetimibe 10 mg against simvastatin 40 mg plus placebo; median follow-up 6 years2 | 7-year Kaplan-Meier primary event rate 32.7% against 34.7% (absolute risk difference 2.0 percentage points; hazard ratio 0.936, 95% CI 0.89 to 0.99; P=0.016); prespecified muscle, gallbladder and hepatic adverse effects and cancer similar in the two groups2 |
| Kastelein and colleagues, ENHANCE, New England Journal of Medicine 20085 | Double-blind randomised trial5 | 720 patients with familial hypercholesterolemia5 | Simvastatin 80 mg with placebo or with ezetimibe 10 mg daily; 24 months5 | Primary outcome, change in carotid-artery intima-media thickness, 0.0058 mm with simvastatin alone and 0.0111 mm with simvastatin plus ezetimibe (P=0.29); secondary intima-media outcomes did not differ significantly5 |
| Baigent and colleagues, SHARP, Lancet 20113 | Randomised double-blind placebo-controlled trial; funded mainly by Merck/Schering-Plough3 | 9270 patients with chronic kidney disease (3023 on dialysis, 6247 not), with no known history of myocardial infarction or coronary revascularisation3 | Simvastatin 20 mg plus ezetimibe 10 mg daily against matching placebo; median follow-up 4.9 years3 | First major atherosclerotic event in 526 (11.3%) against 619 (13.4%) (rate ratio 0.83, 95% CI 0.74 to 0.94; log-rank p=0.0021); non-fatal myocardial infarction or coronary death 213 against 230 (RR 0.92, 95% CI 0.76 to 1.11; p=0.37); all-cause death 1142 against 1115 (RR 1.02, p=0.63)3 |
| Kim and colleagues, RACING, Lancet 20224 | Randomised, open-label, non-inferiority trial; funded by Hanmi Pharmaceutical4 | 3780 patients with atherosclerotic cardiovascular disease at 26 centres in South Korea4 | Rosuvastatin 10 mg with ezetimibe 10 mg against rosuvastatin 20 mg; 3-year primary endpoint4 | Primary composite in 172 (9.1%) against 186 (9.9%) (absolute difference -0.78%; 90% CI -2.39 to 0.83; non-inferiority margin 2.0%); discontinuation or dose reduction by intolerance in 88 (4.8%) against 150 (8.2%)4 |
Deeper analysis: IMPROVE-IT
Cannon and colleagues of the Thrombolysis in Myocardial Infarction (TIMI) Study Group at Brigham and Women's Hospital and Harvard Medical School reported IMPROVE-IT in the New England Journal of Medicine in 2015.2 The 18,144 patients had LDL cholesterol of 50 to 100 mg per deciliter if receiving lipid-lowering therapy, or 50 to 125 mg per deciliter if not, within 10 days of hospitalization for an acute coronary syndrome.2 The primary end point "was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke".2 The median time-weighted average LDL cholesterol level was 53.7 mg per deciliter with simvastatin-ezetimibe and 69.5 mg per deciliter with simvastatin monotherapy.2 The registry entry names Organon and Co as lead sponsor, class industry, and gives an enrollment of 18144.6 Its posted results give the primary Kaplan-Meier percentages as 32.72 with ezetimibe/simvastatin and 34.67 with simvastatin, and a hazard ratio of 0.936 (95% CI 0.887 to 0.988; P value 0.016) from a Cox model.6 For the secondary outcome that counts death from any cause, a major coronary event or non-fatal stroke, the registry gives 38.65 and 40.25 percent, a hazard ratio of 0.948 and a P value of 0.035.6 The registry's adverse events module lists serious adverse events in 3640 of 9067 participants on ezetimibe/simvastatin and 3649 of 9077 on simvastatin.6 The registry's participant flow lists death as the reason for leaving the study in 964 participants in the ezetimibe/simvastatin group and 968 in the simvastatin group.6 The authors report that rates of prespecified muscle, gallbladder and hepatic adverse effects and cancer were similar in the two groups.2 The PubMed record text read for IMPROVE-IT gives no discontinuation figures, no limitations passage and no author disclosures. The record states "Funded by Merck", and its affiliation list places three authors (P.D.L., A.M.T. and T.A.M.) at Merck, Kenilworth, NJ.2 Because both arms took simvastatin, the result compares simvastatin-ezetimibe with simvastatin alone and does not describe ezetimibe on its own.2
Deeper analysis: the IMPROVE-IT malignancy analysis
Giugliano and colleagues of the TIMI Study Group published a prospective malignancy analysis of IMPROVE-IT in JACC CardioOncology in 2020, prompted by "an increased risk of malignancy" reported with simvastatin/ezetimibe in 1,873 patients in the SEAS trial.7 It included the 17,708 post-acute coronary syndrome patients, of 18,144 randomized, who took at least one dose of the study drug; they had been randomized to ezetimibe 10 mg or matching placebo on a background of simvastatin 40 mg, and suspected tumors were adjudicated by oncologists without knowledge of drug assignment.7 In this analysis, 1,470 patients developed the primary malignancy endpoint during a median 6 years of follow-up.7 Kaplan-Meier 7-year rates of malignancy were 10.2% with ezetimibe and 10.3% with placebo (hazard ratio 1.03; 95% CI 0.93 to 1.14; p = 0.56), and malignancy death rates were 3.8% and 3.6% (hazard ratio 1.04; 95% CI 0.88 to 1.23; p = 0.68).7 The authors list limitations, including that "the average follow-up of 6 years might be not long enough to detect a carcinogenic signal, particularly for slowly growing malignancies with a long latency period".7 They also state that part of the malignancy data was collected retrospectively.7 The footnotes state that IMPROVE-IT "was supported by research grants from Merck", that two authors were employed by Merck when the trial was conducted, and that the first author has received a research grant to the institution from Merck for the conduct of IMPROVE-IT and honoraria and consulting fees from Merck.7
Deeper analysis: ENHANCE
Kastelein and colleagues of the Academic Medical Center, Amsterdam, reported ENHANCE in the New England Journal of Medicine in 2008.5 The 720 patients with familial hypercholesterolemia underwent B-mode ultrasonography of the carotid and femoral arteries, and the primary outcome was the change in mean carotid-artery intima-media thickness.5 The primary outcome was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the combined-therapy group (P=0.29), so the trial's primary result was not a significant difference.5 Secondary intima-media outcomes "did not differ significantly between the two groups".5 At the end of the study the mean LDL cholesterol was 192.7+/-60.3 mg per deciliter with simvastatin and 141.3+/-52.6 mg per deciliter with combined therapy.5 Reductions in triglycerides and C-reactive protein differed between the groups by 6.6% and 25.7%, greater with combined therapy.5 The authors write that "Side-effect and safety profiles were similar in the two groups" and conclude that combined therapy "did not result in a significant difference in changes in intima-media thickness" despite decreases in LDL cholesterol and C-reactive protein.5 The PubMed record text read for ENHANCE gives no funding statement, no limitations passage, no discontinuation figures and no author disclosures.
Deeper analysis: SHARP
Baigent and colleagues reported SHARP in the Lancet in 2011, and the report states that the Clinical Trial Service Unit and Epidemiological Studies Unit is part of the University of Oxford.3 The trial randomised 9270 patients with chronic kidney disease, 4650 to simvastatin plus ezetimibe and 4620 to placebo, with a median follow-up of 4.9 years.3 The steering committee changed the key outcome to major atherosclerotic events, with the key comparison being all patients ever allocated simvastatin plus ezetimibe against placebo, including those initially allocated simvastatin; the report cites a statistical analysis plan published before unmasking.3 The allocation produced an average LDL cholesterol difference of 0.85 mmol/L (SE 0.02) "with about two-thirds compliance".3 The main result was 526 (11.3%) first major atherosclerotic events against 619 (13.4%), a rate ratio of 0.83 (95% CI 0.74 to 0.94; log-rank p=0.0021).3 The components differed: non-fatal myocardial infarction or coronary death was non-significant at 213 against 230 (p=0.37), while non-haemorrhagic stroke (131 against 174; p=0.01) and arterial revascularisation (284 against 352; p=0.0036) were lower with the combination.3 There was no significant effect on deaths from any cause (1142 [24.6%] against 1115 [24.1%]; RR 1.02, 95% CI 0.94 to 1.11; p=0.63), and non-vascular deaths were non-significantly more frequent with the combination (668 [14.4%] against 612 [13.2%]; p=0.13).3 Among the 6247 patients not on dialysis, the combination "did not produce significant reductions in any of the prespecified measures of renal disease progression".3 Myopathy occurred in 9 (0.2%) against 5 (0.1%), and the report states no evidence of excess risks of hepatitis (21 against 18), gallstones (106 against 106) or cancer (438 against 439; p=0.89).3 Discontinuation of study treatment was 1533 (33.0%) on the combination and 1669 (36.1%) on placebo, which the report attributes chiefly to more placebo-allocated patients starting non-study statin therapy.3 Stated limitations include that SHARP "did not have sufficient power to assess the effects on major atherosclerotic events separately in dialysis and non-dialysis patients" and that "the trial lacked power for separate assessment of components of major atherosclerotic events".3 The main funder, Merck/Schering-Plough Pharmaceuticals, "participated in initial discussions about trial design, contributed two non-voting observers to the steering committee, and had a right to comment on (but not require changes to) study reports".3 The report adds that it "had no involvement in data collection, analysis, and interpretation, report writing, or the decision to submit for publication", and that SHARP "was initiated, conducted, and interpreted independently of the principal study funder".3 SHARP compared simvastatin plus ezetimibe with placebo, so its principal result does not separate the effect of ezetimibe from that of simvastatin.3
Deeper analysis: RACING
Kim and colleagues of Severance Hospital, Yonsei University College of Medicine, Seoul, reported RACING in the Lancet in 2022.4 The trial randomised 1894 patients to rosuvastatin 10 mg with ezetimibe 10 mg and 1886 to rosuvastatin 20 mg, so the arms differed in both statin dose and ezetimibe.4 The primary endpoint was the 3-year composite of cardiovascular death, major cardiovascular events or non-fatal stroke, in the intention-to-treat population, with a non-inferiority margin of 2.0%.4 It occurred in 172 patients (9.1%) and 186 patients (9.9%), an absolute difference of -0.78% (90% CI -2.39 to 0.83), and the authors conclude the combination was non-inferior.4 LDL cholesterol below 70 mg/dL was seen in 73%, 75% and 72% of the combination group at 1, 2 and 3 years, against 55%, 60% and 58% with rosuvastatin 20 mg.4 Discontinuation or dose reduction of the study drug by intolerance was observed in 88 patients (4.8%) and 150 patients (8.2%), respectively.4 The trial's title describes it as open-label, and the PubMed record text read gives no limitations passage.4 The record gives Hanmi Pharmaceutical as funder, and the disclosure statement says one author "has received institutional research grants from Biotronik and Hanmi".4
Doses reported in studies and on labels
| Source | Dose and route | Comparator | People and n | Duration |
|---|---|---|---|---|
| Zetia label, dosage section | 10 mg orally once daily, with or without food1 | Not applicable | Adults and pediatric patients within the labeled indications1 | Once daily |
| Zetia label, adverse reaction pool, ezetimibe alone | 10 mg daily, oral1 | Placebo | 2,396 patients with primary hyperlipidemia, age range 9 to 86 years1 | Median 12 weeks (range 0 to 39 weeks)1 |
| Zetia label, adverse reaction pool, with a statin | 10 mg/day, oral, with or added to ongoing statin1 | Placebo or active control | 11,308 patients with primary hyperlipidemia1 | Median 8 weeks (range 0 to 112 weeks)1 |
| IMPROVE-IT, 20152 | Ezetimibe 10 mg plus simvastatin 40 mg2 | Simvastatin 40 mg plus placebo | 18,144 patients after acute coronary syndrome | Median follow-up 6 years |
| ENHANCE, 20085 | Ezetimibe 10 mg with simvastatin 80 mg daily5 | Simvastatin 80 mg with placebo | 720 patients with familial hypercholesterolemia | 24 months |
| SHARP, 20113 | Ezetimibe 10 mg plus simvastatin 20 mg daily3 | Matching placebo | 9270 patients with chronic kidney disease | Median follow-up 4.9 years |
| RACING, 20224 | Ezetimibe 10 mg plus rosuvastatin 10 mg4 | Rosuvastatin 20 mg alone | 3780 patients with atherosclerotic cardiovascular disease | 3-year primary endpoint |
Side effects reported
Sources in this part
For ezetimibe alone, the label lists adverse reactions with an incidence of 2% or more and greater than placebo: upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue and influenza.1 In the 10 placebo-controlled trials of 2,396 patients, upper respiratory tract infection occurred in 4.3% against 2.5% on placebo, diarrhea in 4.1% against 3.7%, and arthralgia in 3.0% against 2.2%.1 With a statin, the label lists nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, back pain, influenza, pain in extremity and fatigue at 2% or more and greater than statin alone.1 In controlled combination studies, consecutive transaminase elevations of 3 times the upper limit of normal or more occurred in 1.3% with ezetimibe plus a statin and 0.4% with a statin alone.1 In the fenofibrate trial, cholecystectomy rates were 0.6% with fenofibrate alone and 1.7% with ezetimibe plus fenofibrate, and consecutive transaminase elevations were 4.5% and 2.7%.1 The label states that ezetimibe may cause myopathy and rhabdomyolysis, and that in post-marketing reports most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk.1 Post-marketing reports include thrombocytopenia, pancreatitis, hepatitis, cholelithiasis, cholecystitis and hypersensitivity reactions, reported voluntarily from a population of uncertain size.1 The label lists known hypersensitivity to ezetimibe or any excipient as a contraindication.1 It states that ezetimibe is not recommended in moderate to severe hepatic impairment (Child-Pugh B or C) because of the unknown effects of the increased exposure.1 It states that concomitant use with cyclosporine increases ezetimibe and cyclosporine concentrations, that co-administration with fibrates other than fenofibrate is not recommended, and that cholestyramine decreased mean exposure of total ezetimibe.1
Bloodwork and markers
Sources in this part
The label states that ezetimibe reduces total-C, LDL-C, apolipoprotein B and non-HDL-C in patients with hyperlipidemia.1 It says maximal to near maximal response is generally achieved within 2 weeks and maintained during chronic therapy.1 In the label's homozygous sitosterolemia trial of 37 patients, ezetimibe lowered plasma sitosterol and campesterol by 21% and 24% from baseline, against increases of 4% and 3% with placebo, excluding one subject receiving LDL apheresis.1 The label refers to liver enzyme testing as clinically indicated, with consideration of withdrawal if increases in ALT or AST of 3 times the upper limit of normal or more persist.1 Its dosage section refers to LDL-C assessment "as early as 4 weeks after initiating ZETIA".1
Regulatory and anti-doping status
Sources in this part
The US label for Zetia from Organon LLC gives 2002 as the initial U.S. approval year, and its record was published in 2025 as version 8.1 The WADA Prohibited List 2026 states that it comes into effect on 1 January 2026.8 The text of that list read for this review does not contain the word ezetimibe.8 EMA and TGA documents for ezetimibe were not searched.
Storage and handling
Sources in this part
The label states "Store ZETIA at room temperature between 68°F to 77°F (20°C to 25°C)" and "Protect from moisture".1
What is not known
The label states that the absolute bioavailability of ezetimibe cannot be determined, so the app's 50% has no label figure beside it.1 All four outcome and imaging trials described above gave ezetimibe together with a statin, and each compared a combination with a statin-containing comparator or placebo, so none reports ezetimibe alone against placebo.2,5,3,4 The malignancy analysis authors state that the applicability of their observations to patients excluded from IMPROVE-IT "is unknown".7 Funding and author disclosures for ENHANCE and limitations passages for IMPROVE-IT, ENHANCE and RACING were not in the PubMed record text read.
Frequently asked questions
What is the half-life of ezetimibe?
The Zetia label gives a half-life of approximately 22 hours for both ezetimibe and ezetimibe-glucuronide, and the app lists 22 hours.1
How long does ezetimibe take to reach its peak level?
What is the bioavailability of ezetimibe?
The label states that the absolute bioavailability of ezetimibe cannot be determined, while the app lists 50%.1
What year did the FDA first approve Zetia?
The Zetia label gives 2002 as the initial U.S. approval year.1
Is ezetimibe banned by WADA?
How does ezetimibe work?
The label states that its molecular target has been shown to be the sterol transporter NPC1L1, involved in the intestinal uptake of cholesterol and phytosterols.1
Does food change ezetimibe absorption?
The label states that food had no effect on the extent of absorption of ezetimibe 10-mg tablets, and that high-fat meals increased the ezetimibe Cmax by 38%.1
Did IMPROVE-IT meet its primary endpoint?
In IMPROVE-IT, the 7-year Kaplan-Meier primary event rate was 32.7% with simvastatin-ezetimibe and 34.7% with simvastatin alone (hazard ratio 0.936; 95% CI 0.89 to 0.99; P=0.016), in a trial funded by Merck.2
Did ezetimibe change carotid artery thickness in familial hypercholesterolemia?
In ENHANCE, the change in carotid intima-media thickness was 0.0058 mm with simvastatin alone and 0.0111 mm with simvastatin plus ezetimibe (P=0.29), which the authors describe as no significant difference.5
Guides, tools and comparisons
References
- Organon LLC. Zetia (ezetimibe) tablets, for oral use. US prescribing information, DailyMed record version 8, 2025. DailyMed label
- Cannon CP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015. PMID 26039521
- Baigent C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011. PMID 21663949
- Kim BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet 2022. PMID 35863366
- Kastelein JJ, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008. PMID 18376000
- ClinicalTrials.gov. NCT00202878. IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103). Registry entry with posted results. NCT00202878
- Giugliano RP, et al. Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. JACC CardioOncol 2020. PMID 34396246
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list